To further explore the therapeutic potential of TAGLN2 overexpression, Hwang et al. subcloned the Tagln2 gene downstream of a chimeric endocrine receptor (CER) construct, which targets follicle-stimulating hormone-receptor positive (FSHR+) ovarian tumors. This evidence concerns the gene TAGLN2 and ovarian neoplasm.